Medpace (MEDP) closed the most recent trading day at $447.09, moving +2.06% from the previous trading session. The stock outpaced the S&P 500's daily loss of 0.54%. Elsewhere, the Dow saw an upswing ...

If you are wondering whether Medpace Holdings is still priced attractively after a strong multi year run, it helps to step back and look carefully at what the current share price implies about future ...

Global CRO to support execution of ZIMA-101 study with world's first MAGE-A4-targeting TCR-NK cell therapy productPartnership ...

Levi & Korsinsky, LLP is investigating Medpace Holdings, Inc. (NASDAQ: MEDP) concerning potential securities law claims on behalf of shareholders. The investigation centers on whether the company and ...

Fintel reports that on February 13, 2026, Jefferies upgraded their outlook for Medpace Holdings (NasdaqGS:MEDP) from Hold to Buy. Analyst Price Forecast Suggests 30.24% Upside As of February 4, 2026, ...

Initiated a position in Medpace, increased investment after Q2 earnings miss; believe stock issues are temporary, presenting a buying opportunity. Medpace, a niche leader in CRO industry, operates ...

MADISONVILLE — Medpace Holdings Inc. plans to add 1,500 jobs over the next six years in Cincinnati and invest $150 million to expand its offices and business operations, CEO Dr. August Troendle ...

Medpace operates exclusively on a full-service basis, meaning clients hire them to run entire clinical trial phases end-to-end. The result is a business that scales through operational precision, not ...

Medpace beats analyst estimates on the top and bottom lines in the fourth quarter. Medpace expects full-year 2025 revenue to be in the range of $2.11 billion to $2.21 billion. Up Next: Get 5 Dark ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Medpace’s massive expansion ...